ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 916

Assessing Alternative Selection Criteria for Fibromyalgia Patients within a Multicenter Chronic Pain Claims Database

Mark Gostine1, Fred Davis1, Bradley Roberts2, Rebecca Risko2, Joseph Cappelleri3, Michael Asmus4, Andrew Clair5 and Alesia Sadosky6, 1Michigan Pain Consultants, PC, Grand Rapids, MI, 2ProCare Systems, Inc., Grand Rapids, MI, 3Biostatistics, Pfizer, Inc., Groton, CT, 4North American Medical Affairs, Pfizer, Inc., Middleton, WI, 5Pfizer Inc., New York, NY, 6Pfizer Inc,, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Fibromyalgia: Insights Into Diagnostic Criteria and Symptom Epidemiology

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Diagnosing FM is difficult because there is no specific laboratory test to confirm the disorder. Billing practices dictate that physicians assign ICD-9-CM (Corresponding International Classification of Diseases, Ninth Revision, Clinical Modification) codes based on the procedure for which they use to treat patients.  Since FM pain encompasses many regions of the body and associated problems, physicians commonly do not assign 729.1.   Instead, patients may receive an ICD-9-CM code based on a procedure performed for pain relief, or some other diagnosis commonly associated with a symptom of FM. One of the objectives of this study was to develop a method to identify FM patients who do not meet the inclusion criteria of the 729.1 diagnosis assigned at least twice in a span greater than 12 months apart.  

Methods: The FM predictive model was developed using different techniques.  Among the 9,758 patients, there were 183,540 patient touch points, defined as a distinct time for which information could be obtained from the patient (Physician Health Assessment (PHA) questionnaire, office visits, medication prescriptions, and surgeries).  Over 150 possible predictors were entered into a random forest as a second step for variable reduction. In place of the FM ICD-9-CM code, patients were required to have some type of procedure or visit within the same time frame. A logistic regression model identified the four predictors: musculoskeletal procedures, total unique medications, total unique diagnoses, and days between touch points. The model was validated by using 10-fold cross validation. Propensity score 1:1 matching based on gender, age, length of treatment, and physician was then used to identify a control group of non-malignant chronic pain but without FM group.  A two-sample t-test was used to assess differences between cases and controls for patient variables including total number of procedures, diagnoses, medications, and days between touch points. 

Results: There were 15 diagnoses highly associated with FM that were distinguished by moderate to large effect sizes (Cohen’s d > 0.5).  The diagnoses included chronic pain syndrome, latex allergy, muscle spasm, fasciitis, cervicalgia, thoracic pain, shoulder pain, rheumatoid arthritis, cervical disorders, cystitis, cervical degeneration, anxiety, joint pain, lumbago, and cervical radiculitis. There was a significant association between FM patients and the region where they receive procedures.  Specifically, FM patients are more than four times as likely to receive a procedure in the shoulder (3.55, 5.67) or neck (3.50, 5.02) as non-malignant chronic pain patients.  Overall, FM patients are more likely to receive more procedures encompassing six of the seven regions used for analysis: shoulder, neck, arm, chest, knee, thoracic area (all p < 0.05).  

Conclusion: The predictive model allows a larger selection of FM patients and, by doing so, may assist in accurately targeting more patients for appropriate treatment.  This project gives new insights into the diagnosis, co-morbidities, and treatments associated with FM patients in a pain management setting.


Disclosure: M. Gostine, Pfizer, Inc. 235 E 42nd Street, New York, NY, 2; F. Davis, Pfizer, Inc., 235 E 42nd St., New York, NY, 2; B. Roberts, ProCare Systems, Inc., 3; R. Risko, ProCare Systems, Inc., 3; J. Cappelleri, Pfizer Inc, 3; M. Asmus, Pfizer, Inc., 235 E 42nd Street, New York, NY, 3; A. Clair, Pfizer Inc, 1,Pfizer Inc, 3; A. Sadosky, Pfizer Inc, 3,Pfizer Inc, 1.

To cite this abstract in AMA style:

Gostine M, Davis F, Roberts B, Risko R, Cappelleri J, Asmus M, Clair A, Sadosky A. Assessing Alternative Selection Criteria for Fibromyalgia Patients within a Multicenter Chronic Pain Claims Database [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/assessing-alternative-selection-criteria-for-fibromyalgia-patients-within-a-multicenter-chronic-pain-claims-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-alternative-selection-criteria-for-fibromyalgia-patients-within-a-multicenter-chronic-pain-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology